Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Leptomeningeal Cancer Clear all
Terminated No phase listed Observational
View directory record Official record
Conditions
Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer
Interventions
CNSide
Device
Lead sponsor
Biocept, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Central Nervous System Tumors, Brain Tumors
Interventions
Gallium-67 Citrate (Ga-67), In-111 DTPA (In-111 pentetate)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
LMB-7 immunotoxin
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced May 21, 2026, 6:32 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
Interventions
Mirdametinib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 24 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced May 21, 2026, 6:32 PM EDT
No Longer Available No phase listed Expanded access
View directory record Official record
Conditions
Central Nervous System/Leptomeningeal Neoplasms
Interventions
131I-omburtamab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Childhood Medulloblastoma, Recurrent Childhood Ependymoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Abundant Neuropil and True Rosettes, Metastatic Malignant Neoplasm to the Leptomeninges
Interventions
Intra thecal methotrexate, topotecan, cyclophosphamide
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
Up to 22 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Neuroblastoma, Retinoblastoma, Sarcoma
Interventions
iodine I 131 monoclonal antibody 3F8
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced May 21, 2026, 6:32 PM EDT
Completed No phase listed Interventional Results available
View directory record Official record
Conditions
Breast Cancer, Leptomeningeal Metastasis
Interventions
OncoCEE
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer
Interventions
Dendritic Cell Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Adult, Leptomeningeal Metastasis
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
mafosfamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
9
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Breast Cancer, HER2-positive Breast Cancer
Interventions
Chimeric Antigen Receptor T-Cell Therapy
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, High-grade Glioma, Leptomeningeal Metastasis
Interventions
Azeliragon, CSI
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 1 Interventional Results available
View directory record Official record
Conditions
Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Distal Esophagus Adenocarcinoma, Gastric Cardia Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Esophageal Adenocarcinoma, Unresectable Esophageal Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Adavosertib, Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Duarte, California • Chicago, Illinois • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Brain Cancer
Interventions
Afatinib
Drug
Lead sponsor
Santosh Kesari
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced May 21, 2026, 6:32 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
Interventions
Radiation Therapy, Pertuzumab, Trastuzumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Leptomeningeal Carcinomatosis
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced May 21, 2026, 6:32 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Breast Cancer, Leptomeningeal Disease
Interventions
Tucatinib, Trastuzumab, Capecitabine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors, Leptomeningeal Metastases
Interventions
temozolomide
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Ependymoma, Glioblastoma, Medulloblastoma, Recurrent Metastatic Malignant Neoplasm in the Leptomeninges
Interventions
IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced May 21, 2026, 6:32 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Survey Administration, Volume Modulated Arc Therapy, Hippocampal-Avoidance Craniospinal Irradiation
Procedure · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced May 21, 2026, 6:32 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Metastatic Lung Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Digital Photography, Lumbar Puncture, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Biospecimen Collection
Other · Procedure · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer Female, Leptomeningeal Metastases
Interventions
HER2 BATs
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced May 21, 2026, 6:32 PM EDT